Lv1
50 积分 2024-07-03 加入
NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 7.2025
1小时前
求助中
Back Flow Arteriovenous Shunt Test for Weaning of Venoarterial Extracorporeal Membrane Oxygenator
9天前
已完结
Treatment approaches in patients with advanced non-small cell lung cancer and poor performance status
15天前
已关闭
The global burden of lung cancer: current status and future trends
15天前
已完结
[Guideline for diagnosis and treatment of pediatric allergic rhinitis (2022, revision)]
21天前
已完结
Clinical benefit of anti-PD-1/PD-L1 plus chemotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic non-small cell lung cancer (NSCLC)
21天前
已完结
Design and Rationale for a Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Sugemalimab as Consolidation Therapy in Patients With Limited-Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent or Sequential Chemoradiotherapy: The SURPASS Study
22天前
已完结
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
22天前
已完结
Promising outlook with sugemalimab in non-small-cell lung cancer
22天前
已完结
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
23天前
已完结
皖公网安备34019202002308
